Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results
Ariel Izcovich, Sasha Peiris, Martín Ragusa, Fernando Tortosa, Gabriel Rada, Sylvain Aldighieri, Ludovic Revéiz
Topics & Concepts
IvermectinCoronavirus disease 2019 (COVID-19)MedicineClinical trialMEDLINE2019-20 coronavirus outbreakPublication biasSystematic reviewSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care medicineMeta-analysisInternal medicineVeterinary medicineBiologyPathologyDiseaseOutbreakBiochemistryInfectious disease (medical specialty)Parasitic Diseases Research and TreatmentDermatological diseases and infestationsParasites and Host Interactions